Related Articles
Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer
Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer
DOES MCA CONTRIBUTE TO THE FOLLOW-UP OF BREAST-CANCER PATIENTS BY CA-15-3
New approaches in the diagnostic procedure of malignant pleural effusions
Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection